Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Radiation Toxicity: early-phase trial registry
3 of 14 indexed Radiation Toxicity trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 3 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Radiation Toxicity: 14 US clinical trials tracked, 3 recruiting.
Radiation Toxicity is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Radiation Therapy Oncology Group, running 2 of these trials.
Enrollment posture brief
Registry condition radiation-toxicity
OPEN 3 | RECR 21% | LATE 1 | EARLY 6 | RANK #1230 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Cervical Adenocarcinoma (21% recruiting · 14 trials)
Radiation Toxicity lists 3 open slots (21% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Radiation Toxicity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Radiation Toxicity is recruiting below its size-band peers.
3 of 14 indexed trials (21.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Radiation Toxicity trials is spread across many organizations.
Radiation Therapy Oncology Group accounts for 2 of 14 trials (14.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Radiation Toxicity enrolment sits around 76 participants.
Median target enrolment is 76 among the 13 trials that report a genuine target (sentinel values excluded). 7 of those (53.8%) plan for fewer than 100 participants.
-
Radiation Toxicity splits between interventional and observational designs.
9 interventional and 5 observational studies make up this index (64.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
UNC Lineberger Comprehensive Cancer Center
NCT04700527
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
University of Rochester
NCT05530655
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
Indiana University
NCT06059586
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
University of California, San Francisco
NCT00769223
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Ohio State University Comprehensive Cancer Center
NCT02259218
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Abramson Cancer Center at Penn Medicine
NCT04305613
Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
Wake Forest University Health Sciences
NCT01407770
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
North Central Cancer Treatment Group
NCT00438659
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Case Comprehensive Cancer Center
NCT00255671
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT00006012
Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases
Radiation Therapy Oncology Group
NCT00007007
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
Radiation Therapy Oncology Group
NCT00012012
Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
University of Arizona
NCT00003307
Monoclonal Antibody Therapy in Treating Patients With Leukemia
National Cancer Institute (NCI)
NCT00019227
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Radiation Toxicity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Radiation Toxicity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Radiation Toxicity page
14 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Radiation Toxicity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Radiation Therapy Oncology Group sponsors the most Radiation Toxicity trials on record, review their full trial history before evaluating a specific study. See Radiation Therapy Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Radiation Toxicity condition card totals 14 registered trials; most-linked intervention amifostine trihydrate; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.